Clinical trial ELUCIDATE
A Phase 1/2 open-label multicenter study to assess the safety, pharmacokinetics, and anti-tumor activity of GTAEXS617 in patients with advanced solid tumors.
Cancers | |
---|---|
Organ | Multiple |
Trial status | Trial open for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 1/2 |
Academic trial | Non |
Sponsor | Exscientia AI Limited |
EudraCT Identifier | 2023-508227-13-00 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05985655 |
Last update |